1. Gomatou, G, Tzilas, V, Kotteas, E, et al. Immune checkpoint inhibitor-related pneumonitis. Respiration 2020; 99: 1–11.
Google Scholar2. Wang, DY, Salem, JE, Cohen, JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 1721–1728.
Google Scholar | Crossref | Medline3. Common terminology criteria for adverse events: (CTCAE). v5.0 ed. Bethesda, MD: U.S. Department of Health and Human Services, 2017.
Google Scholar4. Haanen, J, Carbonnel, F, Robert, C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv119–iiv42.
Google Scholar | Crossref | Medline5. Brahmer, JR, Lacchetti, C, Schneider, BJ, et al. Management of immune-related adverse events in patients treated With immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 2018; 36: 1714–1768.
Google Scholar | Crossref | Medline6. Puzanov, I, Diab, A, Abdallah, K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer 2017; 5: 95.
Google Scholar | Crossref | Medline7. Sears, CR, Peikert, T, Possick, JD, et al. Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An official American thoracic society research statement. Am J Respir Crit Care Med 2019; 200: e31–e43.
Google Scholar | Crossref | Medline8. Naidoo, J, Wang, X, Woo, KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017; 35: 709–717.
Google Scholar | Crossref | Medline9. Nishino, M, Ramaiya, NH, Awad, MM, et al. PD-1 Inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 2016; 22: 6051–6060.
Google Scholar | Crossref | Medline10. Wang, H, Zhao, Y, Zhang, X, et al. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: a single-institution retrospective study. Cancer Med 2020; 10: 1–11.
Google Scholar11. Fujii, T, Colen, RR, Bilen, MA, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 2018; 36: 638–646.
Google Scholar | Crossref | Medline12. Sugano, T, Seike, M, Saito, Y, et al. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer 2020; 11: 1052–1060.
Google Scholar | Crossref | Medline13. Suresh, K, Psoter, KJ, Voong, KR, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol 2019; 14: 494–502.
Google Scholar | Crossref | Medline14. Tone, M, Izumo, T, Awano, N, et al. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thorac Cancer 2019; 10: 2006–2012.
Google Scholar | Crossref | Medline15. Fukihara, J, Sakamoto, K, Koyama, J, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors. Clin Lung Cancer 2019; 20: 442–50 e4.
Google Scholar | Crossref | Medline